New Insights from Five-Year Continuous Treatment with Leqembi® in Early Alzheimer's Disease

Significant Findings from Long-Term Study of Leqembi®



In recent news, BioArctic AB's partner, Eisai, shared groundbreaking five-year data from the Clarity AD study at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in Boston. This research sheds light on the sustained benefits of continuous Leqembi® treatment, particularly in the early stages of Alzheimer's disease.

The Clarity AD study, a global, placebo-controlled, double-blind, randomized Phase 3 trial, included a total of 1,795 participants diagnosed with early Alzheimer's disease. Among them, 898 received continuous treatment with Leqembi, while 897 were in the placebo group. Notably, an impressive 95% of those who completed the 18-month core study opted for the subsequent long-term extension, leading to 351 patients receiving continuous treatment for five years.

Long-term Benefits of Treatment


The study’s results revealed an encouraging trend: patients who started treatment earlier, particularly those with low tau levels, demonstrated marked cognitive improvements. Specifically, 62% of these patients exhibited enhancements in cognitive function and daily activities after five years of continuous therapy. Moreover, those who remained on Leqembi for an extended period showed a significant decline in cognitive and functional deterioration compared to matched historical Alzheimer’s disease data. Over three years, patients treated with Leqembi experienced 1.00 points less cognitive decline per the Clinician Dementia Rating – Sum of Boxes (CDR-SB) scale, and this figure escalated to 2.05 points after five years.

According to the results from the Alzheimer's Disease Neuroimaging Initiative (ADNI), the relative risk of patients progressing to the next stage of Alzheimer's was reduced by 36%, with only 61.9% of Leqembi-treated patients transitioning compared to 77.5% in the ADNI group. This reduction emphasizes the critical importance of early intervention. By five years, 49% fewer individuals progressed from early Alzheimer's to moderate or severe dementia while on Leqembi, creating a compelling case for earlier diagnosis and treatment.

An Essential Conclusion on Early Treatment


The examination included an optional tau PET substudy to single out patients with lower tau levels—indicating an earlier stage of Alzheimer's. After five years, 66% of these patients maintained stable cognitive and functional capacity, with 62% showing improvement from their initial baselines. Additional cognitive scales also supported these findings. This reinforces the theory that starting treatment earlier and maintaining continuity could be key to achieving optimal treatment outcomes in Alzheimer’s care.

Safety Profile Remains Consistent


One encouraging aspect of the study was that over five years, no new safety issues related to continuous Leqembi treatment surfaced. The most frequent adverse effect, ARIA-E, seemed limited to the first six months, with incidences declining significantly in the subsequent years. Data indicated that the occurrence rate was 13.5% during the first year but dropped to mere 0.6% by the fifth-year mark, far exceeding the 1.7% experienced by the placebo group over 18 months.

Understanding Alzheimer's Disease and Leqembi®


Alzheimer’s disease, characterized by amyloid-beta (Aβ) and tau pathologies, results from a relentless neurotoxic process that continues beyond plaque accumulation. Leqembi acts effectively against both protofibrils and amyloid plaques, presenting a dual-action mechanism in the fight against this debilitating disease. Leqembi is now approved in 53 countries worldwide, with several additional regions under regulatory review, continuing to establish its foothold in the treatment landscape for Alzheimer’s disease.

The collaboration between BioArctic and Eisai, focused on developing Alzheimer's treatments since 2005, hinges on extensive research and development to fight Alzheimer’s with innovative approaches.

In conclusion, the five-year findings unequivocally demonstrate that early intervention with Leqembi leads to significant advancements in cognitive health, underlining its role in the strategic fight against Alzheimer's disease as one of the first therapies to modify disease progression effectively.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.